About V-set domain-containing T-cell activation inhibitor 1
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is a protein
from Homo sapiens identified by UniProt accession
Q7Z7D3, 282 residues long.
MolForge cross-references it against 0 known binders and
271 disease associations.
Target properties
| Protein name | V-set domain-containing T-cell activation inhibitor 1 |
|---|
| UniProt accession | Q7Z7D3 |
|---|
| Gene | VTCN1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 282 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (271)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.12
- hepatocellular carcinoma · score 0.11
- colorectal carcinoma · score 0.10
- toxoplasmosis · score 0.09
- urinary bladder carcinoma · score 0.09
- triple-negative breast cancer · score 0.09
- esophageal squamous cell carcinoma · score 0.09
- blood protein measurement · score 0.08
- gonorrhea · score 0.08
- pancreatic neoplasm · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q7Z7D3-F1 | alphafold | PREDICTED | 88.52 | — |
Amino-acid sequence (282 residues)
MASLGQILFW SIISIIIILA GAIALIIGFG ISGRHSITVT TVASAGNIGE DGILSCTFEP DIKLSDIVIQ WLKEGVLGLV HEFKEGKDEL SEQDEMFRGR TAVFADQVIV GNASLRLKNV QLTDAGTYKC YIITSKGKGN ANLEYKTGAF SMPEVNVDYN ASSETLRCEA PRWFPQPTVV WASQVDQGAN FSEVSNTSFE LNSENVTMKV VSVLYNVTIN NTYSCMIEND IAKATGDIKV TESEIKRRSH LQLLNSKASL CVSSFFAISW ALLPLSPYLM LK
Explore V-set domain-containing T-cell activation inhibitor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets